In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

The exclusive license agreement follows a collaboration between Kazia and QIMR Berghofer which began in December 2022 and has already led to the filing of supportive patents which include the use of ...

Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

Alvotech obtained its Nasdaq listing via a business combination with Oaktree Acquisition Corp. II in December 2021, and its stock ... second attempts to secure commercial approval for AVT02 ...

SoFi began trading in June 2021, closing its first day at $22.65 ... Investors hope the company’s transition from clinical to commercial stage will be lucrative. ImmunityBio has navigated ...

Immune checkpoint inhibitors (ICIs) such as Keytruda have already transformed the treatment ... can impact their ability to respond to immune checkpoint inhibitors. In 2021, two studies were published ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...